Scholarlink

Background <p>Recent guidelines provide recommendations for diagnosing metabolic dysfunction-associate steatotic liver disease (MASLD) when hepatic steatosis is seen radiographically, but questions remain as to when to pursue imaging for the evidence of hepatic steatosis.</p> Objective <p>We aimed to test the performance of traditional MASLD case-finding cues for detecting MASLD at-risk for advanced fibrosis.</p> Design <p>We performed a cross-sectional study of electronic health record data from a large primary care clinic between 2012 and 2021.</p> Patients <p>Patients with abdominal imaging and inputs for Fibrosis-4 Index (FIB-4) calculation.</p> Main Measures <p>We examined the performance characteristics of type 2 diabetes mellitus (T2DM), a BMI ≥ 30&#xa0;kg/m<sup>2</sup>, or an alanine aminotransferase (ALT) ≥ 40&#xa0;IU/L for detecting the primary outcome of MASLD at-risk for advanced fibrosis. We also tested the optimal thresholds of BMI and ALT for detecting the primary outcome.</p> Key Results <p>The sample included 9000 patients of whom 1683 (19%) patients had MASLD and 696 (8%) had MASLD and an indeterminate-risk or greater for advanced fibrosis. T2DM, BMI ≥ 30&#xa0;kg/m<sup>2</sup>, and ALT ≥ 40&#xa0;IU/L identified 45%, 48%, and 49% of patients with MASLD at-risk for advanced fibrosis. An ALT ≥ 31&#xa0;IU/L had the highest AUC for detecting MASLD at-risk for advanced fibrosis, and the union of T2DM, BMI ≥ 30&#xa0;kg/m<sup>2</sup>, or ALT ≥ 31&#xa0;IU/L had a sensitivity of 89%.</p> Conclusions <p>While historical cues for MASLD case finding had low sensitivities individually, the union of these three, simple, broadly available signals had a high sensitivity for MASLD at-risk for advanced fibrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnosis of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) at Risk for Advanced Fibrosis in a Real-World Primary Care Setting: A Cross-Sectional Study

  • 期刊论文

  • 发表日期：

    2025年7月7日

查看全文
  • Andrew D. Schreiner,
  • Jingwen Zhang,
  • Vincent Bolus,
  • Justin Marsden,
  • Chloe Bays,
  • Ahmed Mohamed,
  • William P. Moran,
  • Patrick D. Mauldin,
  • Mulugeta Gebregziabher,
  • Don C. Rockey

摘要

Background

Recent guidelines provide recommendations for diagnosing metabolic dysfunction-associate steatotic liver disease (MASLD) when hepatic steatosis is seen radiographically, but questions remain as to when to pursue imaging for the evidence of hepatic steatosis.

Objective

We aimed to test the performance of traditional MASLD case-finding cues for detecting MASLD at-risk for advanced fibrosis.

Design

We performed a cross-sectional study of electronic health record data from a large primary care clinic between 2012 and 2021.

Patients

Patients with abdominal imaging and inputs for Fibrosis-4 Index (FIB-4) calculation.

Main Measures

We examined the performance characteristics of type 2 diabetes mellitus (T2DM), a BMI ≥ 30 kg/m2, or an alanine aminotransferase (ALT) ≥ 40 IU/L for detecting the primary outcome of MASLD at-risk for advanced fibrosis. We also tested the optimal thresholds of BMI and ALT for detecting the primary outcome.

Key Results

The sample included 9000 patients of whom 1683 (19%) patients had MASLD and 696 (8%) had MASLD and an indeterminate-risk or greater for advanced fibrosis. T2DM, BMI ≥ 30 kg/m2, and ALT ≥ 40 IU/L identified 45%, 48%, and 49% of patients with MASLD at-risk for advanced fibrosis. An ALT ≥ 31 IU/L had the highest AUC for detecting MASLD at-risk for advanced fibrosis, and the union of T2DM, BMI ≥ 30 kg/m2, or ALT ≥ 31 IU/L had a sensitivity of 89%.

Conclusions

While historical cues for MASLD case finding had low sensitivities individually, the union of these three, simple, broadly available signals had a high sensitivity for MASLD at-risk for advanced fibrosis.